当前位置：
X-MOL 学术
›
Diabetes Obes. Metab.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trial
Diabetes, Obesity and Metabolism ( IF 5.4 ) Pub Date : 2021-08-31 , DOI: 10.1111/dom.14535 Muthiah Vaduganathan 1 , Silvio E. Inzucchi 2 , Naveed Sattar 3 , David H. Fitchett 4 , Anne Pernille Ofstad 5 , Martina Brueckmann 6, 7 , Jyothis T. George 6 , Subodh Verma 8 , Michaela Mattheus 9 , Christoph Wanner 10 , Bernard Zinman 11 , Javed Butler 12
Diabetes, Obesity and Metabolism ( IF 5.4 ) Pub Date : 2021-08-31 , DOI: 10.1111/dom.14535 Muthiah Vaduganathan 1 , Silvio E. Inzucchi 2 , Naveed Sattar 3 , David H. Fitchett 4 , Anne Pernille Ofstad 5 , Martina Brueckmann 6, 7 , Jyothis T. George 6 , Subodh Verma 8 , Michaela Mattheus 9 , Christoph Wanner 10 , Bernard Zinman 11 , Javed Butler 12
Affiliation
To evaluate the effects of empagliflozin versus placebo on subsequent insulin initiation or dosing changes in a large cardiovascular outcomes trial.
中文翻译：
恩格列净对 2 型糖尿病和心血管疾病患者胰岛素启动或强化的影响：来自 EMPA-REG OUTCOME 试验的结果
在一项大型心血管结局试验中评估恩格列净与安慰剂对后续胰岛素启动或剂量变化的影响。
更新日期：2021-11-08
中文翻译：
恩格列净对 2 型糖尿病和心血管疾病患者胰岛素启动或强化的影响：来自 EMPA-REG OUTCOME 试验的结果
在一项大型心血管结局试验中评估恩格列净与安慰剂对后续胰岛素启动或剂量变化的影响。
京公网安备 11010802027423号